ImmuDyne Announces Patient Program in Association With Leading Physicians of the Stone Center

        Print
| Source: Immudyne, Inc.

MT. KISCO, N.Y., Feb. 11, 2014 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) announced today that it has established a partnership with leading physicians of the Stone Center of New Jersey for its new nutritional supplements; iNR Wellness and iNR Wellness MD.

Dr. Joseph V. DiTrolio, Board Member and Treasurer of the Stone Center, stated "At the Stone Center, we see a number of patients who are immune compromised and many patients who are undergoing chemotherapy and radiation therapy. Scientific research has demonstrated that it is better for these type of patients to supplement their therapeutic treatment regimens with a yeast beta-glucan product, such as iNR Wellness MD, than to not take one at all. After carefully reviewing ImmuDyne's data and the body of clinical evidence that demonstrates the numerous health benefits of taking yeast beta-glucan supplements, we concluded that it is in the best interest of our patients to educate them about these immune support supplements."

Karen Kingston, Chief Marketing Officer of ImmuDyne, stated that, "Part of our vision is to educate consumers about the critical importance of supporting your immune system in order to improve your overall health. We are thrilled that some of the leading physicians from the Stone Center support our vision and are eager to begin these type of discussions with their patients. We hope to get this message to several thousand patients through this program. In order to best ensure that their patients are able to afford iNR Wellness MD and iNR Wellness products, we are offering a Patient Discount Program through the physicians of the Stone Center that can be applied online at www.iNRStart.com."

iNRStart.com provides nutritional supplements that are recommended by health and wellness experts worldwide. iNR Wellness, iNR Wellness MD, and iNR Strength all contain PURACERE™. PURACERE™ is a proprietary, clinically researched, doctor-recommended yeast beta 1,3/1,6-D-glucan. PURACERE™ is the purist yeast beta-glucan available, containing no yeast by-products, endotoxins, or ash. PURACERE™ has been clinically proven to prime the immune system and support immune health. Be social and follow iNR Start at https://www.facebook.com/inrstart @iNRStart and https://twitter.com/inrstart.

About the Stone Center

The Stone Center brings together over 120 Urologists from 40 area hospitals, covering eight counties of Northern New Jersey: Bergen, Essex, Hudson, Morris, Passaic, Sussex, Union and Warren. The Stone Center also employs Registered Nurses and Radiology Technologists who are specially trained in urology care. It is one of the largest lithotripsy centers in the United States. 

The Stone Center provides accessible, high quality, cost effective urological services in a clean, safe, and comfortable atmosphere. Their healthcare providers promote individualized care for all patients as well as a feeling of cohesiveness amongst staff. Over 50,000 patients have been treated since The Stone Center's inception in 1987. (http://www.thestonecenter.org)

About ImmuDyne

ImmuDyne manufactures and sells proprietary, clinically researched, doctor-recommended, yeast beta-1,3/1,6-D-glucan nutritional supplements and topical skin care products. ImmuDyne has a portfolio of unique proprietary and patent-protected products with applications in the wellness, skin care, anti-aging, fitness, and health markets. ImmuDyne has offices located in Mt. Kisco, NY, Carlsbad, CA, and Florence, Kentucky. PURACERE, iNR Start, iNR Strength, iNR Wellness, and iNR Wellness MD are trademarks of ImmuDyne, Inc. 2013. ImmuDyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com.

Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

ImmuDyne, Inc.
Mark McLaughlin
+1-914-714-8901